342 related articles for article (PubMed ID: 24357411)
1. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
Ishikawa T
Int J Clin Oncol; 2014 Feb; 19(1):10-5. PubMed ID: 24357411
[TBL] [Abstract][Full Text] [Related]
2. More is better: combination therapies for myelodysplastic syndromes.
Ornstein MC; Mukherjee S; Sekeres MA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
[TBL] [Abstract][Full Text] [Related]
3. Current and future management options for myelodysplastic syndromes.
Bryan J; Jabbour E; Prescott H; Garcia-Manero G; Issa JP; Kantarjian H
Drugs; 2010 Jul; 70(11):1381-94. PubMed ID: 20614946
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Garcia-Manero G; Fenaux P
J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
[TBL] [Abstract][Full Text] [Related]
5. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
[TBL] [Abstract][Full Text] [Related]
7. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
Ball B; Zeidan A; Gore SD; Prebet T
Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
9. The role of decitabine in the treatment of myelodysplastic syndromes.
Atallah E; Kantarjian H; Garcia-Manero G
Expert Opin Pharmacother; 2007 Jan; 8(1):65-73. PubMed ID: 17163808
[TBL] [Abstract][Full Text] [Related]
10. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.
Zeidan AM; Kharfan-Dabaja MA; Komrokji RS
Curr Opin Hematol; 2014 Mar; 21(2):123-30. PubMed ID: 24335709
[TBL] [Abstract][Full Text] [Related]
11. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
[TBL] [Abstract][Full Text] [Related]
12. Treatment of higher-risk myelodysplastic syndrome.
Garcia-Manero G
Semin Oncol; 2011 Oct; 38(5):673-81. PubMed ID: 21943674
[TBL] [Abstract][Full Text] [Related]
13. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
[TBL] [Abstract][Full Text] [Related]
14. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.
Wang R; Gross CP; Maggiore RJ; Halene S; Soulos PR; Raza A; Galili N; Ma X
Leuk Res; 2011 Jul; 35(7):904-8. PubMed ID: 21067809
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Qin Y; Kuang P; Zeng Q; Wu Y; Liu T
Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
Loiseau C; Ali A; Itzykson R
Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
[TBL] [Abstract][Full Text] [Related]
17. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
Merkel DG; Nagler A
Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
[TBL] [Abstract][Full Text] [Related]
18. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
19. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Feld J; Tremblay D; Navada SC; Silverman LR
Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
[TBL] [Abstract][Full Text] [Related]
20. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]